Healios K.K. and Athersys, Inc. have announced a partnership and license agreement that will focus on the development and commercialization of novel cell therapy treatments, including MultiStemA for the treatment of ischemic stroke and potentially other indications, in Japan. The partnership involves MultiStem, a proprietary, patented off-the-shelf stem cell therapy being developed by Athersys, with an initial focus on treating ischemic stroke.